DAIICHI-SANKYO-DS7300-189
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2, Multicenter, Open-Label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination with Atezolizumab with or without Carboplatin as First-Line Induction or Maintenance, in Subjects with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
IIT-GEORGE-I-PREDICT
Phase I/II
OPEN TO ACCRUAL
An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses
MERCK-MK-6070-002
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants with Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer
NRG-LU007
Phase II/III
OPEN TO ACCRUAL
Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
SWOG-S2409-PRISM
Phase II
OPEN TO ACCRUAL
PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer